Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Total Valuation
Karyopharm Therapeutics has a market cap or net worth of $37.93M. The enterprise value is $89.10M.
Market Cap$37.93M
Enterprise Value$89.10M
Share Statistics
Karyopharm Therapeutics has 8,639,904 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,639,904
Owned by Insiders9.42%
Owned by Institutions39.17%
Financial Efficiency
Karyopharm Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is -123.21%.
Return on Equity (ROE)0.41
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-123.21%
Return on Capital Employed (ROCE)-1.66
Revenue Per Employee520.56K
Profits Per Employee-273.91K
Employee Count279
Asset Turnover0.88
Inventory Turnover1.27
Valuation Ratios
The current PE Ratio of Karyopharm Therapeutics is -16.17. Karyopharm Therapeutics’s PEG ratio is -0.40.
PE Ratio-16.17
PS Ratio0.00
PB Ratio-2.49
Price to Fair Value-6.64
Price to FCF-0.30
Price to Operating Cash Flow-4.18
PEG Ratio-0.40
Income Statement
In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M and earned -76.42M in profits. Earnings per share was -0.63.
Revenue145.24M
Gross Profit139.23M
Operating Income-119.44M
Pretax Income-76.36M
Net Income-76.42M
EBITDA-38.60M
Earnings Per Share (EPS)-0.63
Cash Flow
In the last 12 months, operating cash flow was -122.75M and capital expenditures 53.00K, giving a free cash flow of -122.69M billion.
Operating Cash Flow-122.75M
Free Cash Flow-122.69M
Free Cash Flow per Share-14.20
Dividends & Yields
Karyopharm Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-64.10%
50-Day Moving Average5.11
200-Day Moving Average8.76
Relative Strength Index (RSI)44.56
Average Volume (3m)61.64K
Important Dates
Karyopharm Therapeutics upcoming earnings date is Jul 31, 2025, TBA (Confirmed).
Last Earnings DateMay 12, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Karyopharm Therapeutics as a current ratio of 1.70, with Debt / Equity ratio of -44.45%
Current Ratio1.70
Quick Ratio1.64
Debt to Market Cap0.15
Net Debt to EBITDA-3.42
Interest Coverage Ratio-3.19
Taxes
In the past 12 months, Karyopharm Therapeutics has paid 57.00K in taxes.
Income Tax57.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Karyopharm Therapeutics EV to EBITDA ratio is -35.43, with an EV/FCF ratio of -10.72.
EV to Sales9.42
EV to EBITDA-35.43
EV to Free Cash Flow-10.72
EV to Operating Cash Flow-10.73
Balance Sheet
Karyopharm Therapeutics has $38.78M in cash and marketable securities with $91.51M in debt, giving a net cash position of $52.72M billion.
Cash & Marketable Securities$38.78M
Total Debt$91.51M
Net Cash$52.72M
Net Cash Per Share$6.10
Tangible Book Value Per Share-$1.53
Margins
Gross margin is 96.14%, with operating margin of -82.24%, and net profit margin of -52.62%.
Gross Margin96.14%
Operating Margin-82.24%
Pretax Margin-52.58%
Net Profit Margin-52.62%
EBITDA Margin-26.58%
EBIT Margin-26.81%
Analyst Forecast
The average price target for Karyopharm Therapeutics is $23.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$23.25
Price Target Upside429.61% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast1.19%
EPS Growth Forecast61.65%